Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Respiratory Syncytial Virus Vaccine Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

globenewswire.com
PFE Pfizer Inc. is mentioned as a major player in the RSV vaccine market, which is experiencing robust growth. The article does not provide specific positive or negative news about Pfizer itself, but its inclusion as a key company suggests it is part of a growing industry. GSK GlaxoSmithKline plc is highlighted for its Arexvy vaccine receiving FDA approval, the first for older adults. This is a significant positive development, positioning GSK as a leader in a growing market with innovative technology. MRNA Moderna Inc. is listed as a major player in the RSV vaccine market. While the market itself is described as experiencing robust growth, the article provides no specific details about Moderna's current performance or pipeline, indicating a neutral sentiment based on its inclusion. AZN AstraZeneca PLC's acquisition of Icosavax, Inc. for $1.1 billion is presented as a strategic move to enhance its vaccine pipeline, particularly with Icosavax's lead candidate targeting RSV and hMPV. This acquisition signals positive future growth and expansion for AstraZeneca in the vaccine sector.

Respiratory Syncytial Virus Vaccine Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus Vaccine Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.

The respiratory syncytial virus (RSV) vaccine market is experiencing robust growth, driven by several factors. The market size is projected to expand from $1.37 billion in 2025 to $1.95 billion by 2030, with a compound annual growth rate (CAGR) of 7.5% during 2025-2026 and 7.2% during 2026-2030. This growth is primarily attributed to the increasing incidence of RSV-related hospitalizations, unmet medical needs in infant immunization, and heightened awareness of respiratory viral infections. Public health surveillance of seasonal RSV outbreaks and expanded clinical trial activities further bolster market expansion.

The future growth of the RSV vaccine market will be fueled by the approval of novel vaccines, increased government funding for immunization, and rising adoption among elderly populations. There is a growing trend towards preventive healthcare programs and combination vaccine development. The focus on pediatric and geriatric immunization programs is intensifying, supported by substantial investment in advanced vaccine formulations and hospital-based vaccination initiatives aimed at long-term RSV prevention.

A key driver of market expansion is the increasing occurrence of respiratory infections, exacerbated by air pollution, climate change, urbanization, older populations, and drug-resistant pathogens. The RSV vaccine effectively mitigates these infections, especially in infants and older adults. Notably, the UK Health Security Agency reported a significant increase in tuberculosis cases, indicative of the broader trend of rising respiratory infections that will likely stimulate the RSV vaccine market.

Leading companies within the RSV vaccine market are investing in innovative solutions like recombinant protein-based vaccine technologies, which offer enhanced immune protection and safer formulations for high-risk populations. For instance, in May 2023, GlaxoSmithKline plc's Arexvy received FDA approval as the first RSV vaccine targeting older adults, featuring cutting-edge recombinant protein technology that strengthens immune response against the RSV fusion protein.

Acquisitions are reshaping the industry landscape, exemplified by AstraZeneca PLC's acquisition of Icosavax, Inc. for $1.1 billion. This strategic move enhances AstraZeneca's vaccines and immune therapies pipeline, leveraging Icosavax's lead candidate, IVX-A12, which targets both RSV and human metapneumovirus (hMPV).

Regional dynamics reveal that North America was the largest market in 2025, while Asia-Pacific is poised to be the fastest-growing region in the forecast period. Key regions covered include Asia-Pacific, Western and Eastern Europe, North and South America, the Middle East, and Africa. Countries like Australia, India, China, South Korea, Japan, the UK, France, Germany, the USA, and Canada are significant players in this market.

Tariffs are impacting the market by elevating the costs of imported raw materials and specialized components essential for vaccine production. This has increased production expenses and influenced pricing strategies for public immunization programs, while simultaneously promoting localized vaccine manufacturing and strengthening regional supply chains.

The RSV vaccine market is marked by major players such as Pfizer Inc., GlaxoSmithKline plc, and Moderna Inc. The market encompasses sales of protein-based, mRNA, monoclonal antibody, and live-attenuated vaccines, representing factory gate values. These values include related services offered by manufacturers, covering sales through various channels like hospitals and pharmacies.

For comprehensive insights and competitive landscape analysis, the market research report offers an in-depth perspective, detailing trends, opportunities, and critical statistics essential for thriving in the RSV vaccine industry. The report covers transaction values, market size, and shares, enabling stakeholders to make informed strategic decisions.

Report Scope:

Key Attributes:

Key Topics Covered:

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Respiratory Syncytial Virus Vaccine Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Respiratory Syncytial Virus Vaccine Market Attractiveness Scoring and Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Respiratory Syncytial Virus Vaccine Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List of Key Raw Materials, Resources & Suppliers

3.3. List of Major Distributors and Channel Partners

3.4. List of Major End Users

4. Global Respiratory Syncytial Virus Vaccine Market Trends and Strategies

4.1. Key Technologies & Future Trends

4.1.1. Biotechnology, Genomics & Precision Medicine

4.1.2. Artificial Intelligence & Autonomous Intelligence

4.1.3. Digitalization, Cloud, Big Data & Cybersecurity

4.1.4. Industry 4.0 & Intelligent Manufacturing

4.1.5. Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1. Increasing Development of Rsv Vaccines for High-Risk Populations

4.2.2. Rising Focus on Pediatric and Geriatric Immunization Programs

4.2.3. Growing Investment in Advanced Vaccine Formulations

4.2.4. Expansion of Hospital-Based Vaccination Campaigns

4.2.5. Enhanced Emphasis on Long-Term Rsv Prevention

5. Respiratory Syncytial Virus Vaccine Market Analysis of End Use Industries

5.1. Hospitals

5.2. Pediatric Clinics

5.3. Geriatric Care Centers

5.4. Government Immunization Programs

5.5. Specialty Infectious Disease Clinics

6. Respiratory Syncytial Virus Vaccine Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market

7. Global Respiratory Syncytial Virus Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis

7.1. Global Respiratory Syncytial Virus Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Respiratory Syncytial Virus Vaccine Market Size, Comparisons and Growth Rate Analysis

7.3. Global Respiratory Syncytial Virus Vaccine Historic Market Size and Growth, 2020-2025, Value ($ Billion)

7.4. Global Respiratory Syncytial Virus Vaccine Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)

8. Global Respiratory Syncytial Virus Vaccine Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Respiratory Syncytial Virus Vaccine Market Segmentation

9.1. Global Respiratory Syncytial Virus Vaccine Market, Segmentation by Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

9.2. Global Respiratory Syncytial Virus Vaccine Market, Segmentation by Clinical Indications, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

9.3. Global Respiratory Syncytial Virus Vaccine Market, Segmentation by Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10. Respiratory Syncytial Virus Vaccine Market Regional and Country Analysis

10.1. Global Respiratory Syncytial Virus Vaccine Market, Split by Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Respiratory Syncytial Virus Vaccine Market, Split by Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/h6pb2v

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.